First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

TRAX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

First Tracks Biotherapeutics IncNASDAQ: TRAX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows 0.0% year over year

Q1 FY2026 weighted avg shares (diluted) of 34.75M shares rose 0.0% year over year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 2 fiscal years.
  • FY2025 was the lowest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
34.75M— QoQ
Last fiscal yearDec 2025
0— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Weighted Avg Shares (Diluted) vs competitors

How TRAX compares with its peers on the latest reported figures

  • TRAX's FY2025 weighted avg shares (diluted) of 0 shares is the lowest of the 10 companies compared; the peer median is 67.79M shares.
TRAX Competitors Peer median
Weighted Avg Shares (Diluted) for TRAX and competitors
Company Period LTM YoY 3-year CAGR
IMVTImmunovant, Inc.LTM Sep 2026199.36M +24.0%+14.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +45.8%+78.9%
SABSSAB Biotherapeutics, Inc.LTM Jun 202668.13M +634.4%+141.6%
CLYMClimb Bio, Inc.LTM Mar 202667.79M +18.1%+37.1%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202629.47M +0.4%+3.6%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding TRAX) 67.79M+24.0%+33.5%

Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue0152.35M139.61M
Gross Profit0(152.35M)(139.61M)
Gross Margin———
Research & Development97.59M152.35M139.61M
Selling, General & Admin20.87M28.76M39.39M
Operating Expenses118.46M28.76M39.39M
Depreciation & Amortization2.38M2.4M559K
EBITDA(116.09M)(178.7M)(178.45M)
EBITDA Margin———
Operating Income(118.46M)(181.1M)(179.01M)
Operating Margin———
Interest Income12.31M17.38M0
Interest Expense000
Other Income / Expenses12.31M17.4M12.92M
Income Before Tax(106.15M)(163.71M)(166.09M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(106.15M)(163.71M)(166.09M)
Net Margin———
EPS (Basic)(3.05)0.000.00
EPS (Diluted)(3.05)0.000.00
Weighted Avg Shares34.75M00
Weighted Avg Shares (Diluted)34.75M00

First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Intrinsic Alpha fair value

Locked

Current Price

$44.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.